Navigation Links
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
Date:4/2/2009

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the expected timing of the start of clinical trials with MT203, and the potential uses of MT203 and our other product candidates. You are urged to consider statements that include the words "looking forward," "ongoing," "may," "will," "believes," "potential," "expected," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ende
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... 27, 2015  A mere one in seven new ... Hamilton . A new white paper from ... impeding and disrupting manufacturers, success. The white ... Value In Product Development Processes provides insight into: ... how it affects the product development process resulting in: ...
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... Calif., March 24 NuRx,Pharmaceuticals, Inc. (OTC Bulletin Board: ... a Phase I clinical trial of the first-in-class,rexinoid receptor ... expects to complete in the fourth,quarter of this year, ... compound. NRX4204 is the company,s first drug candidate in ...
... March 22 Issue of The Lancet -, ... announced that efficacy results of the randomized ... the March 22 issue of The Lancet ... in,combination with 5-fluorouracil/leucovorin (5-FU/LV), a chemotherapy,regimen called ...
Cached Medicine Technology:NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5
(Date:8/27/2015)... ... August 27, 2015 , ... King Kullen, America’s First ... Founded by Michael J. Cullen in 1930 and recognized by the Smithsonian Institute as ... Still family owned and operated, the Cullen & Kennedy families have created a culture ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch on ... having twelve offices in three counties, LA, Orange and San Bernardino. Their ... Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation ...
(Date:8/27/2015)... ... 27, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and ... Radisson Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , ...
(Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
(Date:8/27/2015)... CT (PRWEB) , ... August 27, 2015 , ... ... devices, announces today that they have launched their new corporate website http://www.Z-Medica.com ... site compliments a product-focused website that was launched last year. , “We ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2Health News:Z-Medica® Launches New Corporate Website 2
... March 4 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, congratulates Dr. Brian Boxer,Wachler on ... this morning,correcting NBCSports.com columnist Alan Abrahamson,s vision with ... the only foldable, minimally invasive lens approved,in the ...
... schools participate in 6th annual KID,HEALTHY--Steps to Healthy ... To combat the,rising trend of childhood obesity ... fifth grade students and parents from Los Angeles,Orange, ... schools and,after-school programs will participate in the KID ...
... acute kidney injury (AKI), an external device containing human ... significantly reduces the risk of death, according to a ... the American Society of Nephrology. , The experimental renal ... desperately ill patients with AKI. "Deployment of the ...
... Argosy Publishing, an award-winning interactive, visual content ... www.visiblebody.com ), the first free, Web-based 3-D interactive ... developed for educators, and health and medical professionals, ... that demonstrates how the human body works. It ...
... Spring Forward - it,s National Sleep Awareness Week, ... physician and,providers at Swedish Medical Center have transitioned ... Sleep Medicine Associates. The new medical group,founded by ... Swedish,Sleep Medicine Institute, will initially operate two centers ...
... the Wildlife Conservation Society, the BioDiversity Research Institute, ... environmental mercurymuch of which comes from human-generated emissionsis ... common loons in the Northeast. , The ... symbolic of northern lakes and wildernessappear in the ...
Cached Medicine News:Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 2Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 3Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 2Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 3Health News:'Renal Assist Device' reduces risk of death from acute kidney failure 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Sleep Medicine Associates Opens New Doors at Swedish - Cherry Hill Campus 2Health News:Scientists find mercury threatens next generation of loons 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: